Citius (CTOR) enters distribution agreement with Cardinal Health (CAH)

Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), a late-stage biopharmaceutical company developing and commercializing first-in-class critical care products, today announced that it has entered into a distribution services agreement with Cardinal Health (NYSE: CAH), a leading provider of pharmaceutical and specialty pharmaceutical distribution services in the United States.

This agreement is designed to help provide access to LYMPHIR™ (denileukin diftitox-cxdl), an innovative immunotherapy FDA-approved for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL), in support of its anticipated U.S. commercial launch.

"This agreement marks a key step forward in our launch readiness efforts," said Leonard Mazur, Chairman and CEO of Citius Oncology and Citius Pharmaceuticals. "Cardinal Health's proven distribution capabilities will help ensure LYMPHIR reaches healthcare providers and patients efficiently and reliably, as we work to build a robust commercial distribution network."

Under the agreement, Cardinal Health will serve as an authorized distributor of record for Citius Oncology providing specialty pharmaceutical distribution services.

You May Also Be Interested In

• Securitize goes public on NYSE after SPAC merger closes
• Innovex closes $95M acquisition of TCO Group AS
• FDA approves Casgevy gene therapy for sickle cell in children 2+